Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: A randomized, placebo-controlled pilot trial

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 243-247

  Meszaros, Zsuzsa Szombathyne ^a   Abdul Malak, Ynesse ^a   Dimmock, Jacqueline A ^a   Wang, Dongliang ^a   Ajagbe, Tolani O ^a   Batki, Steven L ^a,b,c  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

alcohol; nicotine; schizophrenia; smoking; varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ABDOMINAL PAIN; ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NIGHTMARE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SIDE EFFECT; SMOKING; SUICIDAL IDEATION; TOBACCO DEPENDENCE;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; BENZAZEPINES; DIAGNOSIS, DUAL (PSYCHIATRY); DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; PILOT PROJECTS; QUINOXALINES; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84874939741     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182870551     Document Type: Article

References (40)

1. Blanchard JJ, Brown SA, Horan WP, et al. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev. 2000;20:207-234. (Pubitemid 30100433)
2. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
3. Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143:993-997. (Pubitemid 16073948)
4. Anonymous. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000;283:3244-3254.
5. Diwan A, Castine M, Pomerleau CS, et al. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res. 1998;33:113-118. (Pubitemid 28439252)
6. Cuffel BJ, Shumway M, Chouljian TL, et al. A longitudinal study of substance use and community violence in schizophrenia. J Nerv Ment Dis. 1994;182:704-708.
7. Osher FC, Drake RE, Noordsy DL, et al. Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. J Clin Psychiatry. 1994;55:109-113. (Pubitemid 24116437)
8. Gupta S, Hendricks S, Kenkel AM, et al. Relapse in schizophrenia: is there a relationship to substance abuse Schizophr Res. 1996;20:153-156. (Pubitemid 26387513)
9. Olfson M, Mechanic D, Boyer CA, et al. Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis. 1999;187:721-729. (Pubitemid 30036718)
10. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2010;6:CD007253.
11. Cleary M, Hunt G, Matheson S, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2008;1:CD001088.
12. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017. (Pubitemid 44794003)
13. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat. 2009;36:S15-23; quiz S24-5.
14. Schuckit MA. Alcohol-use disorders. Lancet. 2009;373:492-501.
15. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1641-1651. (Pubitemid 47606653)
16. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75:34-56. (Pubitemid 350235398)
17. Batki SL, Dimmock JA, Ploutz-Snyder R, et al. Directly monitored naltrexone reduces heavy drinking in schizophrenia: preliminary analysis of a controlled trial. Alcohol Clin Exp Res. 2009;33(s1):1-346.
18. Larsson A, Svensson L, Soderpalm B, et al. Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol. 2002;28:157-167. (Pubitemid 36124008)
19. Chi H, deWit H. Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin Exp Res. 2003;27:780-786. (Pubitemid 36583360)
20. Targacept, Inc. Inversine (2002): Available at: http://www.targacept.com/ pdf/inversine-pi.pdf. Accessed September 17, 2008.
21. Liu ME, Tsai SJ, Jeang SY, et al. Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia. Psychiatry Res. 2011;190:79-84.
22. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009;110:149-155.
23. Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry. 2008;69:1016. (Pubitemid 351944959)
24. Dutra SJ, Stoeckel LE, Carlini SV, et al. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl). 2011;219:25-34.
25. Hong LE, Thaker GK, McMahon RP, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 2011;68:1195-1206.
26. Steensland P, Simms JA, Holgate J, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA. 2007;104:12518-12523. (Pubitemid 47206170)
27. Fucito LM, Toll BA, Wu R, et al. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl). 2011;215:655-663.
28. McKee SA, Harrison EL, O'Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66:185-190.
29. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version (Patient Edition). Washington D.C.: American Psychiatric Press, Inc.; 2001.
30. Sobell LC, Sobell MB, Maisto SA, et al. Time-line follow-back assessment method. In: Lettieri MA, Sayers, Nelson JE, eds. NIAAA Treatment Handbook Series: Alcoholism Treatment, Assessment, Research Instruments. Washington, DC: US Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, National Institute on Alcohol Abuse and Alcoholism; 1985:530-534.
31. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;22:39-44. (Pubitemid 23355888)
32. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-771.
33. Kay SR, Fiszbein A, Opler LA. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
34. Bechara A, Damasio AR, Damasio H, et al. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition. 1994;50:7-15.
35. Conners CK. The Computerized Continuous Performance Test. [computer program]. Version 2. North Tonawanda, NY: Multi-Health Systems; 1985.
36. Carey KB, Leontieva L, Dimmock J, et al. Adapting motivational interventions for comorbid schizophrenia and alcohol use disorders. Clin Psychol (New York). 2007;14:39-57. (Pubitemid 46351454)
37. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v 4.0. NIH Publication No. 09-5410. Maryland, U.S.A. May 28, 2009, revised June 14, 2010.
38. Green MF, Nuechterlein KH, Kern RS, et al. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry. 2008;165:221-228. (Pubitemid 351704522)
39. Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165:214-220. (Pubitemid 351704521)
40. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213. (Pubitemid 351704520)